Associated Papers
Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors.
Nakamura Y et al.
Nature Medicine, 2025
39284955 (PubMed )
Supplement: 41591_2024_3244_MOESM2_ESM.xlsx › Suppementary_Table_1
Calibration-free NGS quantitation of mutations below 0.01% VAF.
Dai P et al.
Nature Communications, 2021
34675197 (PubMed )
Supplement: 41467_2021_26308_MOESM1_ESM.pdf
Selective multiplexed enrichment for the detection and quantitation of low-fraction DNA variants via low-depth sequencing.
Song P et al.
Nature Biomedical Engineering, 2021
Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient.
Ribeiro MFSA et al.
Npj Precision Oncology, 2021
Proteogenomics Reveals Perturbed Signaling Networks in Malignant Melanoma Cells Resistant to BRAF Inhibition.
Schmitt M et al.
Molecular & Cellular Proteomics : Mcp, 2021
34673281 (PubMed )
Supplement: mmc3.xlsx › S1
Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells.
Hamid AB et al.
Cancers, 2020
The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study.
Punta M et al.
Frontiers in Immunology, 2020
33133066 (PubMed )
Supplement: Table_1.xlsx › Resistance-no-BCR-ABL1
Selfish mutations dysregulating RAS-MAPK signaling are pervasive in aged human testes.
Maher GJ et al.
Genome Research, 2018
30355600 (PubMed )
Supplement: supp_gr.239186.118_Supplemental_Table_S3.xlsx › Table_of_prioritized_calls
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
30053901 (PubMed )
Supplement: 13073_2018_564_MOESM2_ESM.xlsx › 3
Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma.
Yang H et al.
Oncogene, 2017
Mitogen-Activated Protein Kinase Signaling Pathway in Cutaneous Melanoma: An Updated Review.
Acosta AM et al.
Archives of Pathology & Laboratory Medicine, 2016
Targeting the RAS pathway by mitogen-activated protein kinase inhibitors.
Kiessling MK et al.
Swiss Medical Weekly, 2015
Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.
Long GV et al.
Nature Communications, 2014
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.
Van Allen EM et al.
Cancer Discovery, 2014
MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.
Wagle N et al.
Cancer Discovery, 2014
Select a paper to view details